Johns Hopkins Medicine
600 N. Wolfe Street
Baltimore, Maryland, 21287.
Dr. Henry Brem is honored for Clinical Excellence at The National Physician of the Year Awards.
Dr. Henry Brem has transformed the field of Neurosurgery, leading to breakthrough treatments that have extended the lives of brain cancer patients worldwide.
Henry Brem grew up in Northern New Jersey, attending the high school at Yeshiva University in Manhattan. He received his undergraduate degree from New York University, his medical degree from Harvard, and trained in neurosurgery Columbia University, College of Physicians & Surgeons .He joined the staff at John Hopkins in 1984.
Dr. Brem changed the surgical treatment of brain tumors by introducing new approaches for targeted therapy. He developed new classes of polymers and microchips for drug delivery that are custom-made for the agent being developed. He then designed and led the clinical trials demonstrating their safety and efficacy. These were the first new treatments for brain tumors that the FDA had approved in 23 years. Commercially known as Gliadel wafers, this therapy is now used worldwide to intraoperatively deliver chemotherapy directly to the sites of brain tumors.
Dr Brem also carried out the pivotal clinical study that introduced navigational imaging into the neurosurgical suite. His work led to the FDA's approval of the first image guidance computer system for operating on tumors within the brain.
As director of the Department of Neurosurgery and Neurosurgeon-in-Chief at Johns Hopkins, he has built one of the largest brain tumor research and treatment centers in the world, training numerous researchers who have revolutionized the fields of intraoperative imaging, angiogenesis, immunotherapy, and controlled release polymers for drug delivery to the brain.
Dr. Brem sees his career in medicine as a moral imperative -- to provide the best clinical care, while pushing research boundaries to enhance patient's outcomes in the field of neurosurgery. His work is in large part responsible for almost doubling the life expectancy and quality of life brain cancer patients.
He foresees a time when brain cancer will no longer be a life threatening disease, but become a manageable condition.